-
1مورد إلكتروني
المؤلفون: Groen, K, Schjesvold, FH, van der Holt, B, Levin, MD, Seefat, MR, Hansson, M, Leys, MBL, Regelink, JC, Waage, A, Szatkowski, D, Axelsson, P, Do, TH, Svirskaite, A, van der Spek, E, Haukas, E, Knut-Bojanowska, D, Ypma, PF, Blimark, CH, Mellqvist, UH, van de Donk, NWCJ, Sonneveld, P, Klostergaard, A, Vangsted, AJ, Abildgaard, N, Zweegman, S
المصدر: Groen , K , Schjesvold , FH , van der Holt , B , Levin , MD , Seefat , MR , Hansson , M , Leys , MBL , Regelink , JC , Waage , A , Szatkowski , D , Axelsson , P , Do , TH , Svirskaite , A , van der Spek , E , Haukas , E , Knut-Bojanowska , D , Ypma , PF , Blimark , CH , Mellqvist , UH , van de Donk , NWCJ , Sonneveld , P , Klostergaard , A , Vangsted , AJ , Abildgaard , N & Zweegman , S 2023 , ' Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients : Long-term Results of HOVON-126/NMSG 21.13 ' , HemaSphere , vol. 7 , no. 9 , pp. E940 .
مصطلحات الفهرس: article
-
2
-
3مؤتمر
المؤلفون: Gregersen, H, Peceliunas, V, Remes, K, Schjesvold, FH, Abildgaard, N, Nahi, H, Andersen, NF, Vangsted, AJ, Klausen, TW, Helleberg, C, Carlson, K, Frolund, UC, Axelsson, P, Stromberg, O, Blimark, CH, Linder, O, Tsykunova, G, Waage, A, Hansson, M, Gulbrandsen, N
المصدر: BLOOD. 134
مصطلحات موضوعية: Medicin och hälsovetenskap
-
4مؤتمر
المؤلفون: Guenther, A, Mugge, LO, Haenel, M, Schjesvold, FH, Lechner, D, Yaser, S, Hebart, H, Gisslinger, H, Greil, R, Gunsilius, E, Goerner, M, Weisel, K, Durig, J, Elemary, M, Wolleschak, D, Klein, SA, Munder, M, Kiani, A, Nahi, H, Junghanss, C, Campello-Iddison, V, Deniau, Y, Feng, XS, Einsele, H
المصدر: BLOOD. 128(22)
مصطلحات موضوعية: Medicin och hälsovetenskap
-
5دورية أكاديمية
المؤلفون: Pawlyn C; The Institute of Cancer Research, London, UK. charlotte.pawlyn@icr.ac.uk.; The Royal Marsden Hospital NHS Foundation Trust, London, UK. charlotte.pawlyn@icr.ac.uk., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit of Leeds, Leeds, UK., Wei LJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Davies F; Perlmutter Cancer Center, NYU Langone, New York, NY, USA., Nadeem O; Dana-Farber Cancer Institute, Boston, MA, USA., Abdulhaq H; University of California, San Francisco, Fresno Campus, CA, USA., Mateos MV; University Hospital of Salamanca; IBSAL; Institute of Cancer Molecular and Cellular Biology; and CIBERONC, Salamanca, Spain., Laubach J; Dana-Farber Cancer Institute, Boston, MA, USA., Weisel K; University Medical Center of Hamburg-Eppendorf, Hamburg, Germany., Ludwig H; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Jackson G; Northern Centre for Cancer Care, Newcastle Upon Tyne Hospitals Trust, Newcastle Upon Tyne, UK., Morgan G; Perlmutter Cancer Center, NYU Langone, New York, NY, USA., Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA.
المصدر: Blood cancer journal [Blood Cancer J] 2024 Aug 12; Vol. 14 (1), pp. 134. Date of Electronic Publication: 2024 Aug 12.
نوع المنشور: Journal Article; Review
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
مواضيع طبية MeSH: Multiple Myeloma*/mortality , Multiple Myeloma*/therapy , Multiple Myeloma*/drug therapy , Progression-Free Survival*, Humans ; Clinical Trials as Topic ; Neoplasm, Residual ; Biomarkers
-
6دورية أكاديمية
المؤلفون: Hamnvik LHD; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway. Electronic address: lahdah@ous-hf.no., Eide-Olsen S; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Fosseng A; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.
المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Jul 31. Date of Electronic Publication: 2024 Jul 31.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE
-
7تقرير
المؤلفون: Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. fredrikschjesvold@gmail.com., Ludwig H; Department of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna., Delimpasi S; Bone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece., Robak P; Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic., Coriu D; University of Medicine and Pharmacy 'Carol Davila', Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania., Tomczak W; Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin., Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Spicka I; 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Masszi T; Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary., Chernova NG; National Research Center for Haematology, Moscow, Russia., Sandberg A; Oncopeptides AB, Stockholm, Sweden., Thuresson M; Oncopeptides AB, Stockholm, Sweden., Norin S; Oncopeptides AB, Stockholm, Sweden., Bakker NA; Oncopeptides AB, Stockholm, Sweden., Mateos MV; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain., Richardson PG; Dana-Farber Cancer Institute, Boston, MA., Sonneveld P; Erasmus MC Cancer Institute, Rotterdam.
المصدر: Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2331-2336. Date of Electronic Publication: 2024 Jul 01.
نوع المنشور: Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Dexamethasone*/therapeutic use , Dexamethasone*/administration & dosage , Multiple Myeloma*/drug therapy , Quality of Life*, Aged ; Female ; Humans ; Male ; Middle Aged ; Drug Resistance, Neoplasm ; Neoplasm Recurrence, Local/drug therapy ; Phenylalanine/therapeutic use ; Phenylalanine/analogs & derivatives ; Recurrence ; Treatment Outcome
-
8دورية أكاديمية
المؤلفون: Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Ludwig H; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria., Mateos MV; Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain., Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., Abdulhaq H; Department of Hematology and Oncology, University of California, San Francisco, Fresno, California, USA., Norin S; Clinical Science, Oncopeptides AB, Stockholm, Sweden., Thuresson M; Biostatistics, Oncopeptides AB, Stockholm, Sweden., Bakker NA; Clinical Science, Oncopeptides AB, Stockholm, Sweden., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
المصدر: European journal of haematology [Eur J Haematol] 2024 Mar; Vol. 112 (3), pp. 402-411. Date of Electronic Publication: 2023 Nov 15.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE
مواضيع طبية MeSH: Multiple Myeloma*/diagnosis , Multiple Myeloma*/drug therapy , Hematopoietic Stem Cell Transplantation*, Melphalan/*analogs & derivatives , Phenylalanine/*analogs & derivatives , Thalidomide/*analogs & derivatives, Humans ; Melphalan/therapeutic use ; Alkylating Agents/therapeutic use ; Dexamethasone/adverse effects ; Transplantation, Autologous ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
-
9دورية أكاديمية
المؤلفون: Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic. pour.ludek@fnbrno.cz., Szarejko M; University Clinical Centre, Department of Hematology and Transplantology, Gdansk., Bila J; Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo., Spicka I; 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic., Maisnar V; 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic., Jurczyszyn A; Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Faculty of Medicine, Krakow., Grudeva-Popova Z; Department of Clinical Oncology, Medical Faculty, Medical University of Plovdiv, Plovdic, Bulgaria., Hájek R; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Usenko G; City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine., Thuresson M; Oncopeptides AB, Stockholm., Norin S; Oncopeptides AB, Stockholm., Jarefors S; Oncopeptides AB, Stockholm., Bakker NA; Oncopeptides AB, Stockholm., Richardson PG; Dana-Farber Cancer Institute, Boston, MA., Mateos MV; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca.
المصدر: Haematologica [Haematologica] 2024 Mar 01; Vol. 109 (3), pp. 895-905. Date of Electronic Publication: 2024 Mar 01.
نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE
مواضيع طبية MeSH: Antibodies, Monoclonal* , Hematopoietic Stem Cell Transplantation* , Melphalan*/analogs & derivatives , Multiple Myeloma*/diagnosis , Multiple Myeloma*/drug therapy , Neoplasms, Plasma Cell* , Neutropenia* , Phenylalanine*/analogs & derivatives, Humans ; Dexamethasone/therapeutic use ; Proteasome Inhibitors ; Transplantation, Autologous ; United States ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
-
10دورية أكاديمية
المؤلفون: Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: p.sonneveld@erasmusmc.nl., Richardson PG; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Ludwig H; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Hájek R; Department of Hemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic., Abdulhaq H; Department of Hemato-oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; Department of Medicine, University of California, San Francisco, Fresno Campus, CA., Thuresson M; Oncopeptides AB, Stockholm, Sweden., Norin S; Oncopeptides AB, Stockholm, Sweden., Bakker NA; Oncopeptides AB, Stockholm, Sweden., Mateos MV; University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain; Institute of Cancer Molecular and Cellular Biology and CIBERONC, Salamanca, Spain.
المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Sep; Vol. 23 (9), pp. 687-696. Date of Electronic Publication: 2023 May 06.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE
مواضيع طبية MeSH: Multiple Myeloma*/drug therapy, Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/therapeutic use ; Follow-Up Studies ; Melphalan/therapeutic use ; Risk Assessment ; Transplantation, Autologous ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Randomized Controlled Trials as Topic